person · Reporting owner

Takeda Pharma A/S

Disclosed activity across 2 companies

Tapewire entity: 168141
SEC CIK: 0001716226

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Molecular Templates, Inc.MTEM · Entity 85987	10% owner	August 01, 2017	September 08, 2017
Myovant Sciences Ltd.MYOV · Entity 115677	10% owner	March 19, 2018	March 21, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Molecular Templates, Inc.

Report date August 01, 2017 · Filed September 08, 2017

Jointly reported with MILLENNIUM PHARMACEUTICALS INC, Takeda Pharmaceuticals International AG, Takeda A/S, Takeda Europe Holdings B.V., TAKEDA PHARMACEUTICAL CO LTD, Takeda Pharmaceuticals U.S.A., Inc.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,922,993	Reported balance Holding disclosure · report date 2017-08-01 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 2,922,993 F1: These shares are owned directly by Millennium Pharmaceuticals, Inc. ("Millennium"). Millennium is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceutical Company Limited ("Takeda") owns 73.37% of Takeda USA, and Takeda Pharmaceuticals International AG ("Takeda International") owns 26.63% of Takeda USA. Takeda Pharma A/S ("Takeda Denmark") owns 86.83% of Takeda International, and Takeda Europe Holdings B.V. ("Takeda Europe") owns 13.17% of Takeda International. Takeda Denmark is a wholly-owned direct subsidiary of Takeda A/S. Takeda owns 76.09% of Takeda A/S, and Takeda Europe owns 23.91% of Takeda A/S. Takeda Europe is a wholly-owned direct subsidiary of Takeda. Takeda, Takeda USA, Takeda International, Takeda Denmark, Takeda A/S and Takeda Europe each disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are owned directly by Millennium Pharmaceuticals, Inc. ("Millennium"). Millennium is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceutical Company Limited ("Takeda") owns 73.37% of Takeda USA, and Takeda Pharmaceuticals International AG ("Takeda International") owns 26.63% of Takeda USA. Takeda Pharma A/S ("Takeda Denmark") owns 86.83% of Takeda International, and Takeda Europe Holdings B.V. ("Takeda Europe") owns 13.17% of Takeda International. Takeda Denmark is a wholly-owned direct subsidiary of Takeda A/S. Takeda owns 76.09% of Takeda A/S, and Takeda Europe owns 23.91% of Takeda A/S. Takeda Europe is a wholly-owned direct subsidiary of Takeda. Takeda, Takeda USA, Takeda International, Takeda Denmark, Takeda A/S and Takeda Europe each disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein.

Myovant Sciences Ltd.

Report date March 19, 2018 · Filed March 21, 2018

Jointly reported with Takeda Pharmaceuticals International AG, TAKEDA PHARMACEUTICAL CO LTD, Takeda A/S, Takeda Europe Holdings B.V.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2018-03-19 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-03-19 · Sale · Disposed 7,420,625 · Balance 0 F1: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC. F2: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Millennium Pharmaceuticals , Inc.	7,420,625	Reported balance After 2018-03-19 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2018-03-19 · Purchase · Acquired 7,420,625 · Balance 7,420,625 F1: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC. F2: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC.

F2: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 19, 2018 Filed Mar 21, 2018 21:42 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	PurchaseCommon Stock	7,420,625	$18.67	$138,543,068.75	Disclosure SEC source: 0000899243-18-008309 · doc4.xml · nonDerivative · entry 2 Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Takeda A/S · CIK 0001716380 · 10% owner Takeda Europe Holdings B.V. · CIK 0001716379 · 10% owner Takeda Pharma A/S · CIK 0001716226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Millennium Pharmaceuticals , Inc. Disclosed balance after: 7,420,625 F1 · acquired: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC. F2 · acquired: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein. F1 · balance_after: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC. F2 · balance_after: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein. F1 · ownership.nature: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC. F2 · ownership.nature: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein. Read SEC document
March 19, 2018 Filed Mar 21, 2018 21:42 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	SaleCommon Stock	7,420,625	$18.67	$138,543,068.75	Disclosure SEC source: 0000899243-18-008309 · doc4.xml · nonDerivative · entry 1 Takeda Pharmaceuticals International AG · CIK 0001688140 · 10% owner TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner Takeda A/S · CIK 0001716380 · 10% owner Takeda Europe Holdings B.V. · CIK 0001716379 · 10% owner Takeda Pharma A/S · CIK 0001716226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · acquired: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC. F2 · acquired: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein. F1 · balance_after: On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV"); TPAS is owned by Takeda A/S (Denmark) (''T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC. F2 · balance_after: (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.